Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

69 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efavirenz as a substitute for protease inhibitors in HIV-1-infected patients with undetectable plasma viral load on HAART: a median follow-up of 64 weeks.
Rey D, Schmitt MP, Partisani M, Hess-Kempf G, Krantz V, de Mautort E, Bernard-Henry C, Priester M, Cheneau C, Lang JM. Rey D, et al. Among authors: priester m. J Acquir Immune Defic Syndr. 2001 Aug 15;27(5):459-62. doi: 10.1097/00126334-200108150-00006. J Acquir Immune Defic Syndr. 2001. PMID: 11511822 Clinical Trial.
Prednisolone does not prevent the occurrence of nevirapine-induced rashes.
Rey D, Partisani M, Krantz V, Kempf G, Nicolle M, de Mautort E, Priester M, Bernard-Henry C, Lang JM. Rey D, et al. Among authors: priester m. AIDS. 1999 Nov 12;13(16):2307. doi: 10.1097/00002030-199911120-00016. AIDS. 1999. PMID: 10563719 No abstract available.
[Hepatitis A seroprevalence in HIV-infected patients].
Rey D, Frick-Michot E, Partisani M, Hess-Kempf G, Cheneau C, Priester M, Bernard-Henry C, de Mautort E, Wendling MJ, Meyer P, Lang JM. Rey D, et al. Among authors: priester m. Med Mal Infect. 2005 Jul-Aug;35(7-8):402-6. doi: 10.1016/j.medmal.2005.05.003. Med Mal Infect. 2005. PMID: 16139462 French.
Is clinical practice concordant with the changes in guidelines for antiretroviral therapy initiation during primary and chronic HIV-1 infection? The ANRS PRIMO and COPANA cohorts.
Krastinova E, Seng R, Yeni P, Viard JP, Vittecoq D, Lascoux-Combe C, Fourn E, Pahlavan G, Delfraissy JF, Goujard C, Meyer L; ANRS PRIMO and COPANA Cohorts. Krastinova E, et al. PLoS One. 2013 Aug 1;8(8):e71473. doi: 10.1371/journal.pone.0071473. Print 2013. PLoS One. 2013. PMID: 23936509 Free PMC article.
Health-related quality of life of people living with HIV followed up in hospitals in France: comparing trends and correlates between 2003 and 2011 (ANRS-VESPA and VESPA2 national surveys).
Douab T, Marcellin F, Vilotitch A, Protopopescu C, Préau M, Suzan-Monti M, Sagaon-Teyssier L, Lert F, Carrieri MP, Dray-Spira R, Spire B; ANRS-VESPA2 Study Group. Douab T, et al. AIDS Care. 2014;26 Suppl 1:S29-40. doi: 10.1080/09540121.2014.906553. Epub 2014 Apr 14. AIDS Care. 2014. PMID: 24731158
Efficacy and safety of switching to raltegravir plus atazanavir dual therapy in pretreated HIV-1-infected patients over 144 weeks: a cohort study.
Gantner P, Koeppel C, Partisani M, Batard ML, Bernard-Henry C, Cheneau C, De Mautort E, Priester M, Muret P, Sueur C, Fafi-Kremer S, Rey D. Gantner P, et al. Among authors: priester m. Scand J Infect Dis. 2014 Dec;46(12):838-45. doi: 10.3109/00365548.2014.947318. Epub 2014 Sep 17. Scand J Infect Dis. 2014. PMID: 25229167
69 results